- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
March 17th, 2005
Australian biotech pSivida is looking to boost its profile in the United States as it pushes its new silicon-based drug delivery technology, designed to substantially reduce side-effects in patients.
Speaking at a shareholders briefing in Sydney pSivida managing director Gavin Rezos said shrinking consumer tolerance for drug side effects over the past two decades had made its BioSilicon technology very lucrative.
|Related News Press|
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010